Homocysteine, vitamin B metabolites, dopamine-substituting compounds, and symptomatology in Parkinson’s disease : clinical and therapeutic considerations
Phokaewvarangkul, Onanong ; Bhidayasiri, Roongroj ; Garcia-Ruiz, Pedro ; Odin, Per LU
; Riederer, Peter
and Müller, Thomas
(2023)
In Journal of Neural Transmission
130(11).
p.1451-1462
- Abstract
Emerging studies suggest a correlation between elevated plasma homocysteine (hcy) levels and the risk of atherosclerosis, vascular disorders, and neurodegenerative diseases, including Parkinson's disease (PD). This narrative review delves into the intricate relationships between Hcy, vitamin B metabolites, dopamine-substituting compounds, and various symptoms of PD. Patients undergoing a long-term L-dopa/dopa-decarboxylase inhibitor (DDI) regimen, especially without a concurrent catechol-O-methyl transferase (COMT) inhibitor or methyl group-donating vitamin supplementation, such as vitamins B6 and B12, exhibit an elevation in Hcy and a decline in vitamin B metabolites. These altered concentrations appear to be associated with heightened... (More)
Emerging studies suggest a correlation between elevated plasma homocysteine (hcy) levels and the risk of atherosclerosis, vascular disorders, and neurodegenerative diseases, including Parkinson's disease (PD). This narrative review delves into the intricate relationships between Hcy, vitamin B metabolites, dopamine-substituting compounds, and various symptoms of PD. Patients undergoing a long-term L-dopa/dopa-decarboxylase inhibitor (DDI) regimen, especially without a concurrent catechol-O-methyl transferase (COMT) inhibitor or methyl group-donating vitamin supplementation, such as vitamins B6 and B12, exhibit an elevation in Hcy and a decline in vitamin B metabolites. These altered concentrations appear to be associated with heightened risks of developing non-motor symptoms, including peripheral neuropathy and cognitive disturbances. The review underscores the impact of levodopa metabolism via COMT on homocysteine levels. In light of these findings, we advocate for the supplementation of methyl group-donating vitamins, notably B6 and B12, in patients undergoing a high-dose L-dopa/DDI regimen, particularly those treated with L-dopa/carbidopa intestinal gel (LCIG) infusion.
(Less)
- author
- Phokaewvarangkul, Onanong
; Bhidayasiri, Roongroj
; Garcia-Ruiz, Pedro
; Odin, Per
LU
; Riederer, Peter
and Müller, Thomas
- organization
- publishing date
- 2023
- type
- Contribution to journal
- publication status
- published
- subject
- keywords
- Homocysteine, Levodopa, Neuropathy, Parkinson’s disease, Vitamin B metabolites
- in
- Journal of Neural Transmission
- volume
- 130
- issue
- 11
- pages
- 1451 - 1462
- publisher
- Springer
- external identifiers
-
- pmid:37603058
- scopus:85168449679
- ISSN
- 0300-9564
- DOI
- 10.1007/s00702-023-02684-9
- language
- English
- LU publication?
- yes
- id
- fc16d740-c74c-436f-9cd4-a0d7668130b1
- date added to LUP
- 2023-11-13 14:29:39
- date last changed
- 2024-04-25 06:45:24
@article{fc16d740-c74c-436f-9cd4-a0d7668130b1,
abstract = {{<p>Emerging studies suggest a correlation between elevated plasma homocysteine (hcy) levels and the risk of atherosclerosis, vascular disorders, and neurodegenerative diseases, including Parkinson's disease (PD). This narrative review delves into the intricate relationships between Hcy, vitamin B metabolites, dopamine-substituting compounds, and various symptoms of PD. Patients undergoing a long-term L-dopa/dopa-decarboxylase inhibitor (DDI) regimen, especially without a concurrent catechol-O-methyl transferase (COMT) inhibitor or methyl group-donating vitamin supplementation, such as vitamins B6 and B12, exhibit an elevation in Hcy and a decline in vitamin B metabolites. These altered concentrations appear to be associated with heightened risks of developing non-motor symptoms, including peripheral neuropathy and cognitive disturbances. The review underscores the impact of levodopa metabolism via COMT on homocysteine levels. In light of these findings, we advocate for the supplementation of methyl group-donating vitamins, notably B6 and B12, in patients undergoing a high-dose L-dopa/DDI regimen, particularly those treated with L-dopa/carbidopa intestinal gel (LCIG) infusion.</p>}},
author = {{Phokaewvarangkul, Onanong and Bhidayasiri, Roongroj and Garcia-Ruiz, Pedro and Odin, Per and Riederer, Peter and Müller, Thomas}},
issn = {{0300-9564}},
keywords = {{Homocysteine; Levodopa; Neuropathy; Parkinson’s disease; Vitamin B metabolites}},
language = {{eng}},
number = {{11}},
pages = {{1451--1462}},
publisher = {{Springer}},
series = {{Journal of Neural Transmission}},
title = {{Homocysteine, vitamin B metabolites, dopamine-substituting compounds, and symptomatology in Parkinson’s disease : clinical and therapeutic considerations}},
url = {{http://dx.doi.org/10.1007/s00702-023-02684-9}},
doi = {{10.1007/s00702-023-02684-9}},
volume = {{130}},
year = {{2023}},
}